science

Owkin

Owkin is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Owkin rather than just read about it. In short: Owkin is a French-American artificial intelligence and biotech company that builds agentic AI to analyze data, identify new treatments, optimize clinical trials and develop AI diagnostics. The company uses multimodal patient data from academic institutions and hospitals to train its AI models for data analysis, drug discovery, and drug development.

Key takeaways

Owkin belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Owkin to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Owkin from memory before moving on to harder problems.

Reference excerpt

Owkin is a French-American artificial intelligence and biotech company that builds agentic AI to analyze data, identify new treatments, optimize clinical trials and develop AI diagnostics. The company uses multimodal patient data from academic institutions and hospitals to train its AI models for data analysis, drug discovery, and drug development. Owkin collaborates with pharmaceutical companies around the world to improve their therapeutic programs.

History Owkin was founded in Paris in 2016, by Thomas Clozel, a clinical research doctor and son of Jean-Paul and Martine Clozel founders of Swiss biotech Actelion, and Gilles Wainrib, a professor of Artificial Intelligence. Owkin has raised over $308 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.

Technologies

Agentic AI Owkin uses agentic AI to support biomedical research by helping scientists “explore, refine, and validate” hypotheses. Their AI uses a single natural language interface that allows scientists to interact conversationally with the scientific literature and their data.

MOSAIC MOSAIC (Multi Omic Spatial Atlas in Cancer) aims to build one of the largest spatial multiomics datasets in oncology and involves collaboration between Owkin, Nanostring Technologies, the University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité-Universitätsmedizin Berlin.

OwkinZero Owkin developed a biological reasoning AI model, OwkinZero, trained on a proprietary question and answer dataset created using its MOSAIC platform. In evaluations on biological reasoning tasks, OwkinZero outperformed several other large language models, including ChatGPT. Owkin's long-term research goal is to develop biological artificial super intelligence based on such models.

Federated learning Owkin uses federated learning, a decentralized machine learning technique, to train machine learning models with multiple data providers. Federated learning allows data providers to collaborate without moving or sharing their data. The MELLODDY project, an initiative that included Owkin, ten pharmaceutical companies, and six other partners, applied federated learning to train AI on datasets without having to share proprietary data. The aim was to improve drug discovery and they built a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). The first results of the project were published in July 2022.

Transfer learning Transfer learning is a machine learning technique that allows a model pre-trained on one task to be used on another related task. Owkin uses transfer learning to work on very small datasets. Owkin's model (CHOWDER) is able to understand high-level graphic patterns, such as tumors, that are themselves relying on very low-level visual patterns, in order to fully learn the tumor's visual pattern.

Products and Services

KPro K Pro is an intelligent research agent that uses artificial intelligence and multiomics data to support researchers’ and scientists’ efforts to expedite biomedical insights. It was first released in May 2025 and includes features such as user data upload, biomedical skills library, biological tissues visualization and cell-identification, data licensing, and data explorer.

Partnerships

Amgen Owkin collaborated with Amgen to test the ability of AI to improve cardiovascular prediction.

AstraZeneca AstraZeneca partnered with Owkin in 2026 to build AI agents in addition to a 3-year license for K Pro. In 2024, Owkin and AstraZeneca partnered to develop an AI-powered tool specifically designed to prescreen for gBRCA mutations using digital pathology slides. Identifying mutations in the BRCA1 and BRCA2 genes plays an important role in identifying risk for developing certain types of cancers, including breast and ovarian. The tool aims to speed up and increase access to gBRCS testing.

Sanofi Sanofi partnered with Owkin in 2026 to build AI agents in additions to a 3-year license for K Pro. In November 2021 Owkin entered a strategic alliance with Sanofi. The alliance included a $180 million equity investment, and a $90 million discovery and development partnership focused on Sanofi's oncology efforts in four different cancers. Sanofi used Owkin's technology to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment.

Bristol-Myers Squibb In June 2022, Owkin entered a strategic alliance with Bristol-Myers Squibb to help them design potentially more precise and efficient clinical trials. The collaboration initially focused on cardiovascular disease, and has the potential to expand into projects in other therapeutic areas.

MSD In December 2023, Owkin entered a strategic alliance with MSD to develop and commercialize AI-powered digital pathology diagnostics for the EU market that could be used to identify patients suitable for immunotherapies.

Servier In October 2023, Owkin and Servier started a multi-year partnership focused on developing “better-targeted therapies” in oncology and other disease areas. The partnership's first two projects were in translational medicine and digital pathology.

MOSAIC MOSAIC was formed by Owkin, Nanostring Technologies, the University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité-Universitätsmedizin Berlin. It uses spatial omics, multimodal patient data, and artificial intelligence, and aims to “offer unprecedented information on the structure of tumors” and guide new treatments.

Publications Owkin's research on AI/ML has led to a number of publications that focus on machine learning methodologies and the development of predictive models for different disease areas, mainly oncology.

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Owkin

Start with the simplest possible case. Write down what Owkin claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Owkin before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Owkin ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Owkin

In research: Owkin appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Owkin in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Owkin is common in secondary-school and first-year university syllabi. It links to neighbouring topics 2016 establishments in France, Artificial intelligence companies, Biotechnology companies, so understanding it makes those chapters shorter.
In everyday life: Look for Owkin outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Owkin in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Owkin means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Owkin out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Owkin in simple terms?

Why does Owkin matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Owkin?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Owkin.